“
Mental health is an enormous business; in the United States, more money is spent on mental health conditions than any other medical specialty, with an estimated $201 billion spent in 2013 alone and an estimated increase to $280 billion by 2020 (Substance Abuse and Mental Health Services Administration, 2014). More than half of the budget for the American Psychiatric Association is income received directly from pharmaceutical companies, and drug-makers are the most frequent and largest donors of mental health advocacy groups (see, e.g., Harris, 2009). Speaking and consulting gigs for the pharmaceutical industry can earn psychiatrists up to $1 million or more in direct fees per year,4 and at least 70% of the professionals making up the task force for the DSM were tied to pharmaceutical companies (Cosgrove & Krimsky, 2012), raising concerns about corporate interests reflected in practice and policy and accusations of disease mongering (Moynihan, Heath, & Henry, 2002). The incentive for ensuring the medical and biological framework for conceptualizing problems in living is huge.
”
”